170 related articles for article (PubMed ID: 16473650)
1. Vascular toxicity of antineoplastic agents.
Shahab N; Haider S; Doll DC
Semin Oncol; 2006 Feb; 33(1):121-38. PubMed ID: 16473650
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of cancer therapy.
Floyd JD; Nguyen DT; Lobins RL; Bashir Q; Doll DC; Perry MC
J Clin Oncol; 2005 Oct; 23(30):7685-96. PubMed ID: 16234530
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system toxicity from cancer therapies.
Schiff D; Wen P
Hematol Oncol Clin North Am; 2006 Dec; 20(6):1377-98. PubMed ID: 17113469
[TBL] [Abstract][Full Text] [Related]
4. Vascular toxicity of chemotherapeutic agents.
López-Miranda V; Herradón E; González C; Martín MI
Curr Vasc Pharmacol; 2010 Sep; 8(5):692-700. PubMed ID: 19758112
[TBL] [Abstract][Full Text] [Related]
5. Aging: an important risk factor in chemotherapy-associated vascular diseases.
Roselli M; Guadagni F; Ferroni P
Expert Rev Anticancer Ther; 2013 Aug; 13(8):899-901. PubMed ID: 23984891
[No Abstract] [Full Text] [Related]
6. Vascular toxicity associated with antineoplastic agents.
Doll DC; Yarbro JW
Semin Oncol; 1992 Oct; 19(5):580-96. PubMed ID: 1411655
[TBL] [Abstract][Full Text] [Related]
7. [Vascular disorders following chemotherapy].
van der Lelie J; von dem Borne AE
Ned Tijdschr Geneeskd; 1995 Nov; 139(45):2296-9. PubMed ID: 7501060
[No Abstract] [Full Text] [Related]
8. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients.
Hazin R; Abuzetun JY; Daoud YJ; Abu-Khalaf MM
Curr Opin Ophthalmol; 2009 Jul; 20(4):308-17. PubMed ID: 19491683
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target therapy-associated CNS complications].
Kishida S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1659-64. PubMed ID: 18931566
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular complications of cancer and cancer treatments.
Custodio CM
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):27-45, v-vi. PubMed ID: 18194748
[TBL] [Abstract][Full Text] [Related]
12. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
de Castro G; Awada A
Curr Opin Oncol; 2006 Jul; 18(4):307-15. PubMed ID: 16721122
[TBL] [Abstract][Full Text] [Related]
13. Vascular effects of cancer treatments.
Campia U
Vasc Med; 2020 Jun; 25(3):226-234. PubMed ID: 32539632
[TBL] [Abstract][Full Text] [Related]
14. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues.
Chen Y; Jungsuwadee P; Vore M; Butterfield DA; St Clair DK
Mol Interv; 2007 Jun; 7(3):147-56. PubMed ID: 17609521
[TBL] [Abstract][Full Text] [Related]
15. Central and peripheral nervous system toxicity of common chemotherapeutic agents.
Sioka C; Kyritsis AP
Cancer Chemother Pharmacol; 2009 Apr; 63(5):761-7. PubMed ID: 19034447
[TBL] [Abstract][Full Text] [Related]
16. Renal disease in patients with cancer.
Finkel KW; Foringer JR
Nat Clin Pract Nephrol; 2007 Dec; 3(12):669-78. PubMed ID: 18033226
[TBL] [Abstract][Full Text] [Related]
17. Vascular toxicity associated with antineoplastic agents.
Doll DC; Ringenberg QS; Yarbro JW
J Clin Oncol; 1986 Sep; 4(9):1405-17. PubMed ID: 3528405
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
19. Late toxicity in survivors from adolescent cancers.
Pentheroudakis G; Pavlidis N
Cancer Treat Rev; 2007 Nov; 33(7):656-63. PubMed ID: 17640814
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
